Executives at Amgen made the case for MariTide's differentiation, while Merck's CEO contended Keytruda's coming loss of exclusivity can be managed.

BioWorld™ published by Clarivate Plc (NYSE:CLVT), a leading global provider of transformative intelligence, has released its ...

Exelixis, Inc. EXEL announced its preliminary financial results for fiscal 2024 and provided guidance for fiscal 2025.

For patients with unresectable, nonmetastatic hepatocellular carcinoma, transarterial chemoembolization (TACE) with the ...

For over a century, radiotherapy has revolutionised cancer treatment. Technological advancements aim to deliver high doses to ...

Kidney stones are pebble-sized deposits that form when there’s too much salt and minerals in your urine. Learn whether men or women are more at risk, what passing one feels like, and how big ...

Management of advanced renal cell carcinoma remains a persistent clinical challenge with high morbidity and mortality for a large proportion of patients. Until recently, available medical ...

(n = 65) Randomized, discontinuation trial (part 2 of a two-part trial) Sorafenib Placebo Rate of progression-free survival 12 wk after randomization: 50% (sorafenib) vs. 18% (placebo) (p = 0.0077 ...

A panelist discusses how Non-muscle Invasive Bladder Cancer (NMIBC) treatment varies by risk stratification (low, intermediate, and high-risk), with BCG immunotherapy being standard for high-risk ...

Series Recaps Biopharma, MedTech, and Science Trends and Breakthroughs That Shaped the Year LONDON, Jan. 16, 2025 /PRNewswire/ -- BioWorld published by Clarivate Plc (NYSE:CLVT), a leading ...